Affibodies and aptamers, for instance, exhibit the potential of combining nanomolar affinities for GPC3 with minimal immunogenicity, and their small size promises even more rapid blood clearance and tumor penetration [42,43,44]. The gene discussed is GPC3; the disease is neoplasm.